Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 13, 1998

View Archived Issues

Company Profile: Telik

Xoma completes phase II enrollment in psoriasis study

Kosan enters research collaboration with J&J

Rhone-Poulenc Rorer's Estalis approved in 12 E.U. countries

Inex demonstrates effectiveness of new antisense drug

Perprazole filings to be made within a year

Diatide brings first Techtide product to market

Neutrophil inhibitor peptides available for licensing from RCT

Scientists report significant finding related to the genetics of insulin-dependent diabetes

Nicotinic acetylcholine receptor ligands from Pfizer for addictive and CNS disorders

Ono's new PGE2 derivatives show binding affinity for EP2 receptors

Trega concludes phase I testing of HP-228 inhalation formulation

Antiatherosclerotic compounds prepared by Bayer scientists

Lundbeck develops new antipsychotic agents acting on D1 receptors

Novel central 5-HT1A receptor agonists characterized in binding and animal studies

Erythromycin derivatives for Gram-positive infections disclosed by Hoechst Marion Roussel

Antiatherogenic activity of antioxidant BO-653 explored in animal models

Demegen's Peptidyl MIM compound D4B effectively treats infected wounds

Gene therapy targeting Tie2 receptor tyrosine kinase evaluated as antiangiogenic strategy

Promising preclinical findings reported for PI-88; phase I testing begins next month

5-HT2C agonist shows potential for treating OCD and depression

NCIC-CTG leads major international trial for new ovarian cancer compound

Matrix reports promising phase III results for IntraDose in breast cancer

LXR redirects resources to three strategic development programs

GeneMedicine receives NIH grant to pursue AAT Gene Medicine

Pharmos successfully completes phase II head trauma study

Oralin cleared for phase III trials in Ecuador; regulatory clearance expected by year-end

DepoTech and Chiron submit NDA for DepoCyt

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...